HALO 202: Randomized phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock, Tara E. Seery, William P. Harris, Darren S. Sigal, Fadi Braiteh, Paul S. Ritch, Mark M. Zalupski, Nathan Bahary, Paul E. Oberstein, Andrea Wang-Gillam, Wilson Wu, Dimitrios Chondros, Ping Jiang, Sihem Khelifa, Jie Pu, Carrie Aldrich, Andrew E. Hendifar

Research output: Contribution to journal › Article › peer-review

176 Scopus citations

Fingerprint

Dive into the research topics of 'HALO 202: Randomized phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences